# ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

> **NCT07037420** · PHASE2 · RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** ALXN2420
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07037420
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-28
- **Primary completion:** 2027-01-08
- **Final completion:** 2027-11-11
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07037420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07037420, "ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07037420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*